Related Experiment Video
Updated: Jul 2, 2025

Induction and Diagnosis of Tumors in Drosophila Imaginal Disc Epithelia
Published on: July 25, 2017
Spontaneous expression of the CIC::DUX4 fusion oncoprotein from a conditional allele potently drives sarcoma
Peter G Hendrickson1, Kristianne M Oristian1, MaKenna R Browne1,2
1Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USA.
Abstract:
CIC::DUX4 sarcoma (CDS) is a rare but highly aggressive undifferentiated small round cell sarcoma driven by a fusion between the tumor suppressor Capicua (CIC) and DUX4. Currently, there are no effective treatments and efforts to identify and translate better therapies are limited by the scarcity of patient tumor samples and cell lines. To address this limitation, we generated three genetically engineered mouse models of CDS (Ch7CDS, Ai9CDS, and TOPCDS). Remarkably, chimeric mice from all three conditional models developed spontaneous soft tissue tumors and disseminated disease in the absence of Cre-recombinase. The penetrance of spontaneous (Cre-independent) tumor formation was complete irrespective of bi-allelic Cic function and the distance between adjacent loxP sites. Characterization of soft tissue and presumed metastatic tumors showed that they consistently expressed the CIC::DUX4 fusion protein and many downstream markers of the disease credentialing the models as CDS. In addition, tumor-derived cell lines were generated and ChIP-seq was preformed to map fusion-gene specific binding using an N-terminal HA epitope tag. These datasets, along with paired H3K27ac ChIP-sequencing maps, validate CIC::DUX4 as a neomorphic transcriptional activator. Moreover, they are consistent with a model where ETS family transcription factors are cooperative and redundant drivers of the core regulatory circuitry in CDS.
Insights
Researchers developed new mouse models for CIC::DUX4 sarcoma (CDS), a rare cancer. These models spontaneously develop tumors, aiding the study of this aggressive disease and the search for effective therapies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- CIC::DUX4 sarcoma (CDS) is a rare, aggressive cancer driven by the CIC::DUX4 fusion.
- Effective treatments are lacking due to limited patient samples and cell lines.
Purpose of the Study:
- To generate and validate genetically engineered mouse models for CDS.
- To overcome limitations in studying CDS due to sample scarcity.
Main Methods:
- Generation of three conditional mouse models (Ch7CDS, Ai9CDS, TOPCDS).
- Observation of spontaneous, Cre-independent tumor formation.
- Characterization of tumors and generation of tumor-derived cell lines.
- ChIP-seq to map CIC::DUX4 binding and H3K27ac profiles.
Main Results:
- All three models developed spontaneous soft tissue tumors and disseminated disease.
- Tumor formation was complete and Cre-independent.
- Validated CIC::DUX4 as a neomorphic transcriptional activator.
- Identified ETS family transcription factors as drivers of CDS regulatory circuitry.
Conclusions:
- The developed mouse models are effective tools for studying CDS.
- CIC::DUX4 acts as a potent transcriptional activator in CDS.
- ETS factors play a crucial role in the core regulatory network of CDS.
More Related Videos
Related Concept Videos
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Induced Pluripotent Stem Cells
Somatic...

